p16INK4a Antibody / CDKN2A

Immunofluorescence: 1:25,Western blot: 1:500-1:2000,Flow cytometry: 1:25 (1x10e6 cells),Immunohistochemistry (FFPE): 1:25

The stated application concentrations are suggested starting points. Titration of the CDKN2A antibody may be required due to differences in protocols and secondary/substrate sensitivity.

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Purified

In 1X PBS, pH 7.4, with 0.09% sodium azide

A portion of amino acids 104-131 from the human protein was used as the immunogen for the CDKN2A antibody.

This CDKN2A antibody is available for research use only.

Nuclear, cytoplasmic

Antigen affinity purified

Human

P42771